Overall, this study embarks on a journey to explore the potential of repositioning FDA-approved drugs as HDAC3 inhibitors, addressing the pressing need for novel therapeutic strategies in the battle against complex diseases, with a particular emphasis on cancer. This evidence concerns the gene HDAC3 and cancer.